Medarex licenses BioWa antibody technology
This article was originally published in Scrip
Kyowa Hakko's US antibody subsidiary BioWa has non-exclusively licensed its Complegent potency-enhancing technology toMedarex. The US firm will apply the technology, which enhances antibody complement-dependent cytotoxity by introducing isotype chimaerism, to investigational therapeutic antibodies against selected targets, in return for undisclosed up front, milestone, royalty and other fee payments. Medarex is developing antibodies for cancer, autoimmune disorders and other indications and has already licensed in BioWa's Potelligent technology, which enhances antibody antigen-dependent cellular cytotoxicity.